GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Callitas Health Inc (OTCPK:MPHMF) » Definitions » 14-Day RSI

Callitas Health (Callitas Health) 14-Day RSI : N/A (As of May. 04, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Callitas Health 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-04), Callitas Health's 14-Day RSI is N/A.

The industry rank for Callitas Health's 14-Day RSI or its related term are showing as below:

MPHMF's 14-Day RSI is not ranked *
in the Biotechnology industry.
Industry Median: 48.86
* Ranked among companies with meaningful 14-Day RSI only.

Competitive Comparison of Callitas Health's 14-Day RSI

For the Biotechnology subindustry, Callitas Health's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Callitas Health's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Callitas Health's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Callitas Health's 14-Day RSI falls into.



Callitas Health  (OTCPK:MPHMF) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Callitas Health  (OTCPK:MPHMF) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Callitas Health 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Callitas Health's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Callitas Health (Callitas Health) Business Description

Traded in Other Exchanges
N/A
Address
734 - 1055 Dunsmuir Street, Vancouver, BC, CAN, V7X 1B1
Callitas Health Inc is a clinical-stage company. It is engaged in developing technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The company's products offering includes ToConceive, C-103 Reformulated Orlistat, and Extrinsa. ToConceive is a fertility enhancing moisturizer. It is clinically proven to increase a woman's own natural conception lubrication, called transudate, to aid in conception. Orlistat is FDA-approved for weight management and sold by Roche as Xenical (prescription) and by GlaxoSmithKline as alli. Extrinsa focuses on women with orgasm and arousal difficulties. The topical, local, and the non-systemic product is also non-hormonal and does not affect the central nervous system.